Serum Vascular Adhesion Protein-1 Predicts 10-Year Cardiovascular and Cancer Mortality in Individuals With Type 2 Diabetes

doi:10.2337/db10-0607

CNU IR > College of Sustainable Environment and Recreation > Dept. of Occupational Safety > Periodical Articles > Item 310902800/27022

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/27022

Title:	Serum Vascular Adhesion Protein-1 Predicts 10-Year Cardiovascular and Cancer Mortality in Individuals With Type 2 Diabetes
Authors:	Li, Hung-Yuan Jiang, Yi-Der Chang, Tien-Jyun Wei, Jung-Nan Lin, Mao-Shin Lin, Cheng-Hsin Chiang, Fu-Tien Shih, Shyang-Rong Hung, Chi Sheng Hua, Cyue-Huei David, J.Smith Vanio, Jani Chuang, Lee-Ming
Contributors:	職業安全衛生系
Keywords:	Sensitive Amine Oxidase Hepatocellular-Carcinoma Colorectal-Cancer Leukocyte Binding Tumor Endothelium P-Selectin Disease Risk Overexpression Adipocytes
Date:	2011-03
Issue Date:	2013-10-23 11:55:48 (UTC+8)
Publisher:	Amer Diabetes Assoc
Abstract:	OBJECTIVE Vascular adhesion protein-1 (VAP-1) participates in inflammation and catalyzes the breakdown of amines to produce aldehyde, hydrogen peroxide, and ammonia. Serum VAP-1 correlates positively with both acute hyperglycemia and diabetes. We conducted a cohort study to evaluate whether serum VAP-1 predicts 10-year survival in type 2 diabetic patients. RESEARCH DESIGN AND METHODS Between July 1996 and June 2003, we enrolled 661 type 2 diabetic subjects at National Taiwan University Hospital. Serum VAP-1 in the samples obtained at enrollment was measured by time-resolved immunofluorometric assay. The vital status of all subjects was ascertained by linking their data with computerized death certificates in Taiwan. RESULTS The medium follow-up period was 10.4 years. Subjects with serum VAP-1 in the highest tertile had a hazard ratio (HR) of 2.19 (95% CI 1.17–4.11) for all-cause mortality adjusted for age, sex, smoking, history of cardiovascular disease, obesity, hypertension, hemoglobin A1c, diabetes duration, total cholesterol, use of statins, abnormal ankle-brachial index, estimated glomerular filtration rate (eGFR), and proteinuria. The adjusted HRs for logarithmically transformed serum VAP-1 were 5.83 (95% CI 1.17–28.97) for cardiovascular mortality, 6.32 (95% CI 1.25–32.00) for mortality from cardiovascular and diabetic causes, and 17.24 (95% CI 4.57–65.07) for cancer mortality. There were four variables, including age, serum VAP-1, proteinuria, and eGFR, which could enhance mortality prediction significantly. CONCLUSIONS Serum VAP-1 can predict 10-year all-cause mortality, cardiovascular mortality, and cancer mortality independently in type 2 diabetic subjects. Serum VAP-1 is a novel biomarker that improves risk prediction over and above established risk factors
Relation:	Diabetes , 60(3), pp.993-999
Appears in Collections:	[Dept. of Occupational Safety] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	1890	View/Open

Loading...